Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 237,214
  • Shares Outstanding, K 97,619
  • Annual Sales, $ 32,310 K
  • Annual Income, $ -237,090 K
  • EBIT $ -187 M
  • EBITDA $ -187 M
  • 60-Month Beta 2.44
  • Price/Sales 7.14
  • Price/Cash Flow N/A
  • Price/Book 15.81

Options Overview Details

View History
  • Implied Volatility 110.83% (+1.29%)
  • Historical Volatility 77.27%
  • IV Percentile 34%
  • IV Rank 22.12%
  • IV High 216.03% on 02/19/25
  • IV Low 80.94% on 09/04/25
  • Expected Move (DTE 14) 0.39 (16.16%)
  • Put/Call Vol Ratio 0.93
  • Today's Volume 79
  • Volume Avg (30-Day) 720
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 50,412
  • Open Int (30-Day) 54,863
  • Expected Range 2.03 to 2.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 6
  • High Estimate -0.17
  • Low Estimate -0.34
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +50.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.09 +15.79%
on 12/02/25
2.80 -13.57%
on 11/12/25
-0.36 (-12.95%)
since 11/05/25
3-Month
2.09 +15.79%
on 12/02/25
4.54 -46.66%
on 10/08/25
-0.34 (-12.32%)
since 09/05/25
52-Week
0.91 +165.93%
on 04/07/25
4.54 -46.66%
on 10/08/25
+0.51 (+26.70%)
since 12/05/24

Most Recent Stories

More News
Editas: Q3 Earnings Snapshot

Editas: Q3 Earnings Snapshot

EDIT : 2.42 (-0.41%)
Editas Medicine Announces Third Quarter 2025 Results and Business Updates

In vivo  preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy ...

EDIT : 2.42 (-0.41%)
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 2.42 (-0.41%)
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...

AUTL : 1.5500 (-1.27%)
AVAI : 0.2875 (-2.58%)
DNLI : 19.96 (-0.75%)
EDIT : 2.42 (-0.41%)
XNCR : 17.30 (-4.63%)
Editas Medicine Unveils Promising Preclinical Data on EDIT-401

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Editas Medicine...

EDIT : 2.42 (-0.41%)
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported  in vivo preclinical proof-of-concept data for EDIT-401,...

EDIT : 2.42 (-0.41%)
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 2.42 (-0.41%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

USA News Group News Commentary

VCYT : 44.61 (-5.91%)
QURE : 21.33 (-6.20%)
HUM : 257.85 (+1.91%)
AVAI : 0.2875 (-2.58%)
EDIT : 2.42 (-0.41%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

/CNW/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in...

VCYT : 44.61 (-5.91%)
HUM : 257.85 (+1.91%)
QURE : 21.33 (-6.20%)
AVAI : 0.2875 (-2.58%)
EDIT : 2.42 (-0.41%)
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway...

EDIT : 2.42 (-0.41%)

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 2.61
2nd Resistance Point 2.55
1st Resistance Point 2.49
Last Price 2.42
1st Support Level 2.37
2nd Support Level 2.31
3rd Support Level 2.25

See More

52-Week High 4.54
Fibonacci 61.8% 3.15
Fibonacci 50% 2.72
Last Price 2.42
Fibonacci 38.2% 2.30
52-Week Low 0.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar